Kamada Ltd. (NASDAQ:KMDA) Short Interest Up 33.3% in January

Kamada Ltd. (NASDAQ:KMDA) was the recipient of a large increase in short interest during the month of January. As of January 15th, there was short interest totalling 23,200 shares, an increase of 33.3% from the December 31st total of 17,400 shares. Based on an average daily volume of 63,600 shares, the days-to-cover ratio is presently 0.4 days. Currently, 0.1% of the shares of the company are short sold.

Kamada Trading Down 0.4 %

NASDAQ:KMDA traded down $0.03 during trading hours on Thursday, hitting $6.71. 37,540 shares of the stock traded hands, compared to its average volume of 164,636. The firm has a 50 day moving average price of $6.38 and a 200 day moving average price of $5.84. The firm has a market cap of $385.69 million, a price-to-earnings ratio of 23.96, a PEG ratio of 0.96 and a beta of 0.98. Kamada has a fifty-two week low of $4.74 and a fifty-two week high of $8.00.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price target on shares of Kamada in a research note on Friday, January 10th.

Hedge Funds Weigh In On Kamada

A hedge fund recently bought a new stake in Kamada stock. Public Employees Retirement System of Ohio purchased a new stake in shares of Kamada Ltd. (NASDAQ:KMDA) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 14,270 shares of the biotechnology company’s stock, valued at approximately $77,000. Institutional investors and hedge funds own 20.38% of the company’s stock.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.